0.441

4.15% -0.0191

Pre-market: .44 -0.001 -0.23%

Applied Therapeutics Inc (APLT)

Overview News Price History Option Chain Financials Discussions Forecast

Applied Therapeutics Inc stock is traded at $0.441, with a volume of 1.83M. It is down -4.15% in the last 24 hours and down -13.26% over the past month. Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

Previous Close:

$0.4601

Open:

$0.44

24h Volume:

1.83M

Relative Volume:

0.52

Market Cap:

$51.31M

Revenue:

Net Income/Loss:

$-119.76M

P/E Ratio:

-0.3267

EPS:

-1.35

Net Cash Flow:

$-55.17M

1W Performance:

-15.73%

1M Performance:

-13.26%

6M Performance:

-94.74%

1Y Performance:

-93.08%

1-Day Range:

$0.435

$0.4641

1-Week Range:

$0.435

$0.5598

52-Week Range:

$0.435

$10.62

Applied Therapeutics Inc Stock (APLT) Company Profile

Name

Applied Therapeutics Inc

Sector

Healthcare (1161)

Industry

Biotechnology (676)

Phone

212-220-9226

Address

545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY

Employee

Twitter

@Applied_Tx

Next Earnings Date

2025-03-31

Latest SEC Filings

APLT's Discussions on Twitter

Compare APLT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
APLT Applied Therapeutics Inc	0.441	51.31M	0	-119.76M	-55.17M	-1.35
VRTX Vertex Pharmaceuticals Inc	483.49	124.48B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	625.60	67.45B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	583.62	35.60B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	266.83	34.53B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	274.78	29.15B	3.81B	-644.79M	-669.77M	-6.24

Applied Therapeutics Inc Stock (APLT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-23-24	Downgrade	William Blair	Outperform → Mkt Perform
Dec-02-24	Downgrade	UBS	Buy → Neutral
Nov-29-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jul-31-24	Initiated	William Blair	Outperform
Mar-26-24	Initiated	RBC Capital Mkts	Outperform
Feb-22-24	Initiated	Leerink Partners	Outperform
Jan-04-22	Downgrade	Barclays	Overweight → Equal Weight
Aug-27-21	Downgrade	Goldman	Neutral → Sell
Jun-25-21	Resumed	Goldman	Neutral
Oct-08-20	Initiated	Truist	Buy
Apr-22-20	Initiated	Goldman	Buy
Feb-27-20	Initiated	Barclays	Overweight
Jun-10-19	Initiated	Citigroup	Buy
Jun-10-19	Initiated	Cowen	Outperform
Jun-10-19	Initiated	Robert W. Baird	Outperform

View All

Applied Therapeutics Inc Stock (APLT) Latest News

Mar 31, 2025

Applied Therapeutics Delays Yearly Report Filing - TipRanks

Mar 31, 2025

Applied Therapeutics files Form 12b-25 with SEC - TipRanks

Mar 31, 2025

Applied Therapeutics Files Form 12b-25 with the Securities and Exchange Commission - GlobeNewswire

Mar 31, 2025

Applied Therapeutics Requests SEC Extension: What This Means for 2024 Financial Results - Stock Titan

Mar 31, 2025

146,900 Shares in Applied Therapeutics, Inc. (NASDAQ:APLT) Purchased by Swiss National Bank - Defense World

Mar 31, 2025

Mar 22, 2025

Shareholders of Applied Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights – APLT - ACCESS Newswire

Mar 22, 2025

Lost Money on Applied Therapeutics, Inc.(APLT)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire

Mar 22, 2025

Mar 21, 2025

Applied Therapeutics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights – APLT - ACCESS Newswire

Mar 21, 2025

APLT LAWSUIT ALERT: Levi & Korsinsky Notifies Applied Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire

Mar 21, 2025

Mar 19, 2025

Applied Therapeutics appoints new Chief Regulatory Officer By Investing.com - Investing.com South Africa

Mar 19, 2025

Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer - citybiz

Mar 19, 2025

APLT DEADLINE ALERT: Applied Therapeutics Investors have until February 18 before Expiration of the Class Action DeadlineContact BFA Law if You Lost Money - Louisiana First News

Mar 19, 2025

Applied Therapeutics Names Todd Baumgartner As Chief Regulatory Officer - Nasdaq

Mar 19, 2025

Applied Therapeutics appoints new Chief Regulatory Officer - Investing.com

Mar 19, 2025

Applied Therapeutics Strengthens Drug Approval Push With 12-Time FDA Success Veteran - Stock Titan

Mar 19, 2025

Mar 16, 2025

Brokerages Set Applied Therapeutics, Inc. (NASDAQ:APLT) Price Target at $6.10 - MarketBeat

Mar 16, 2025

Mar 13, 2025

Applied Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your RightsAPLT - ACCESS Newswire

Mar 13, 2025

Applied Therapeutics, Inc. (NASDAQ:APLT) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World

Mar 13, 2025

Mar 12, 2025

APPLIED THERAPEUTICS Earnings Preview: Recent $APLT Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 12, 2025

A look into Applied Therapeutics Inc (APLT)’s deeper side - SETE News

Mar 12, 2025

Mar 09, 2025